China Drug Deals Raise Supply Concerns, US Panel Warns
A US congressional commission says pharmaceutical licensing deals with Chinese biotechnology companies could increase American dependence on Chinese innovation. Its analysis of 57 deals comes as both governments consider restrictions affecting biotechnology trade and investment.

The National Security Commission on Emerging Biotechnology warned in a new analysis that China's drug supply chain ambitions could threaten US access to future treatments.
The commission examined 57 pharmaceutical deals from the beginning of 2023 through the month before its analysis. It found that Western drugmakers increasingly license treatments from Chinese companies, directing US capital toward China's pharmaceutical industry.
The warning comes as both countries consider restrictions affecting biotechnology. China proposed export restrictions on certain technologies, including cell and gene therapy platforms. Such therapies aim to treat disease using cells or genetic material.
Deals move earlier in development
In a typical licensing deal, a Chinese biotechnology company sells a multinational drugmaker the rights to develop or commercialize a treatment.
Western companies use the arrangements to shift some of the burden of drug discovery and verify early results. AstraZeneca, Bristol Myers Squibb and Pfizer are among the drugmakers drawn by China's life sciences investment and the promise of faster trials and approvals.
The commission found that deals increasingly rely on preclinical data, collected before a treatment reaches human trials. Upfront payments are also arriving earlier in research and development.
That timing gives Chinese partners capital and expertise in developing and commercializing treatments, the commission said. Royalties and stakes in joint ventures can flow back to China, funding research and infrastructure and attracting talent.
Commission Executive Director Caitlin Frazer said the deals risk eroding US biotechnology research and development. She added: “This trend should be alarming for policymakers.”
Washington weighs investment restrictions
The Trump administration proposed new screening requirements for certain deals with Chinese life sciences companies, as well as outright prohibitions for others.
The administration cited risks that investments could support biological weapons or surveillance technologies, or make US supply chains overly dependent on one country.
Under the proposal, cash-based deals involving royalties and payments tied to development milestones would remain permitted. Equity investments in Chinese firms would be prohibited, and certain joint ventures could also face restrictions, according to an analysis by Sidley.
Congress established the commission to examine the national security implications of emerging biotechnology. The panel called the proposed restrictions a prudent step, while urging policymakers to strengthen US innovation.
Brookings Institution senior fellow Marta Wosińska has noted that drug shortages can delay treatment for seizures, infections or severe pain.
In an earlier report to Congress, the commission described a hypothetical scenario in which Beijing withheld a breakthrough treatment from American patients during a conflict in Taiwan.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Lifestyle · Food & HealthWhat Is Raynaud’s Syndrome? Why Fingers Turn White in the Cold
Lifestyle · Food & Health4 Ways Walking After Meals Helps Your Body, Doctors Say
Lifestyle · Food & Health4 Reasons to Eat Oatmeal, According to Nutrition Experts
Lifestyle7 Signs Your Social Battery Is Running Low (and Why You Keep Cancelling Plans)




















